Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

NCT01197534 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

913

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: fostamatinib
DRUG: fostamatinib
DRUG: placebo, fostamatinib

Sponsor

AstraZeneca